In patients with heart failure, when is iron replacement therapy indicated and why?

Iron Replacement Therapy in Heart Failure: Indications and Rationale

Intravenous iron replacement therapy should be considered in all symptomatic patients with heart failure and reduced ejection fraction (HFrEF, LVEF <40-45%) who have iron deficiency, defined as ferritin <100 μg/L OR ferritin 100-299 μg/L with transferrin saturation <20%, regardless of whether anemia is present. 1, 2

Why Treat Iron Deficiency in Heart Failure?

Iron deficiency occurs in 40-70% of heart failure patients and is independently associated with:

• Reduced exercise capacity and functional status
• Impaired quality of life
• Worse prognosis and increased hospitalizations
• More severe heart failure symptoms

These effects occur even without anemia, making iron deficiency a distinct therapeutic target separate from anemia management 1, 2.

Specific Indications for IV Iron Therapy

Patient Criteria:

• NYHA Class II-IV symptoms despite guideline-directed medical therapy
• LVEF <40-45% (strongest evidence in HFrEF; limited data for HFpEF)
• Iron deficiency by the following criteria:
  • Ferritin <100 μg/L (absolute deficiency), OR
  • Ferritin 100-299 μg/L with TSAT <20% (functional deficiency) 1, 2

Clinical Benefits Demonstrated:

The evidence base shows IV iron (specifically ferric carboxymaltose) improves:

• Exercise capacity (6-minute walk test, peak VO2)
• NYHA functional class
• Quality of life scores
• Reduction in heart failure hospitalizations (RR 0.74 in AFFIRM-AHF trial) 1

Importantly, these benefits occur independent of anemia status 1.

Why Intravenous Rather Than Oral Iron?

Oral iron supplementation is NOT effective in heart failure patients 1, 2. The IRONOUT HF trial definitively showed no improvement with oral iron 1. This failure is due to:

• Poor gastrointestinal absorption in heart failure
• Elevated hepcidin from chronic inflammation blocking iron absorption
• Inadequate iron delivery to replete stores
• May require >6 months to achieve repletion (if at all) 2

Screening Recommendations

All newly diagnosed heart failure patients should have iron status evaluated (Class I recommendation) 2. Additionally, screen:

• Symptomatic patients despite optimal medical therapy
• During routine follow-up 1-2 times per year
• After hospitalization for heart failure 2

Critical testing requirement: Both ferritin AND transferrin saturation must be measured simultaneously and evaluated together. Do not rely on MCV, MCH, or MCHC—these are unreliable in heart failure 2.

Common Pitfalls to Avoid

1. Don't wait for anemia to develop before treating iron deficiency—the benefits are independent of hemoglobin levels
2. Don't use standard iron deficiency cutoffs (e.g., ferritin <30 μg/L)—heart failure requires higher thresholds due to inflammation
3. Don't prescribe oral iron—it doesn't work in this population
4. Don't forget to recheck iron status at 3 months after correction dose to assess for recurrent deficiency 2

Contraindications and Cautions

Absolute contraindications:

• Hypersensitivity to IV iron products
• Active bacteremia
• Iron overload
• Anemia not due to iron deficiency 2

Use caution in:

• Acute/chronic infection
• History of severe allergies or asthma
• Autoimmune conditions (SLE, rheumatoid arthritis)
• Hemoglobin >15 g/dL (no safety data) 2

Guideline Strength

The 2022 AHA/ACC/HFSA guidelines and 2016 ESC guidelines both provide Class IIa, Level of Evidence A recommendations for IV iron therapy in symptomatic HFrEF patients with iron deficiency 1, 2. This represents strong evidence from multiple randomized controlled trials (FAIR-HF, CONFIRM-HF, EFFECT-HF, AFFIRM-AHF).

Note on mortality: While IV iron reduces hospitalizations, no trial has yet demonstrated cardiovascular mortality reduction, though meta-analyses suggest potential benefit 1.